Return Peptide Library
AVA6000
DLevel 1 evidenceAVA6000
Other/Research
Basic Information
Categories
FAP-activating peptide-drug conjugate
Overview
Avacta's FAP-activated doxorubicin peptide-drug conjugate demonstrates significant disease control rates in the Phase I FOCUS trial of tumor microenvironment-activated chemotherapy.
Efficacy Rating
Research in Oncology: Peptide-Drug Conjugates
Evidence Level
D-Rank
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.